Edwards Lifesciences Corp (EW) Financials
Annual revenue, profitability and per-share results for Edwards Lifesciences Corp, as reported in SEC filings.
Revenue • FY2025
$6.07B
▲ 11.5%YoY
Net income • FY2025
$1.07B
▼ 74.3%YoY
Gross margin • FY2025
78.0%
Diluted EPS • FY2025
$1.83
▼ 73.7%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $6.07B | $1.07B | $4.73B | $1.83 | $1.33B | 20.8% | +11.6% |
| FY2024 | $5.44B | $4.17B | $4.32B | $6.97 | $289.9M | 25.4% | -9.4% |
| FY2023 | $6B | $1.4B | $4.63B | $2.30 | $642.8M | 25.6% | +11.6% |
| FY2022 | $5.38B | $1.52B | $4.3B | $2.44 | $973.6M | 32.5% | +2.9% |
Figures as reported in Edwards Lifesciences Corp's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a EW filing.
Get an email when EW files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.